Liu, X., Liu, X., Qiao, T., Chen, W., & Yuan, S. (2016). Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: Results from seven randomized controlled trials. Dove Medical Press.

Liu, Xiaoqun, Xiangdong Liu, Tiankui Qiao, Wei Chen, and Sujuan Yuan. Efficacy and Safety of Adding an Agent to Bevacizumab/taxane Regimens for the First-line Treatment of Her2-negative Patients With Locally Recurrent or Metastatic Breast Cancer: Results From Seven Randomized Controlled Trials. Dove Medical Press, 2016.

Liu, Xiaoqun, et al. Efficacy and Safety of Adding an Agent to Bevacizumab/taxane Regimens for the First-line Treatment of Her2-negative Patients With Locally Recurrent or Metastatic Breast Cancer: Results From Seven Randomized Controlled Trials. Dove Medical Press, 2016.